L
Lixin Jiang
Researcher at Peking Union Medical College
Publications - 92
Citations - 10633
Lixin Jiang is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 26, co-authored 84 publications receiving 9005 citations. Previous affiliations of Lixin Jiang include Cardiovascular Institute of the South & Yale University.
Papers
More filters
Journal ArticleDOI
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent,Martin J Landray,Christina Reith,Jonathan Emberson,David C. Wheeler,Charles R.V. Tomson,Christoph Wanner,Vera Krane,Alan Cass,Jonathan C. Craig,Bruce Neal,Lixin Jiang,Lai Seong Hooi,Adeera Levin,Lawrence Y. Agodoa,Mike Gaziano,Bertram L. Kasiske,Robert J. Walker,Ziad A. Massy,Bo Feldt-Rasmussen,Udom Krairittichai,Vuddidhej Ophascharoensuk,Bengt Fellström,Hallvard Holdaas,Vladimir Tesar,Andrzej Wiecek,Diederick E. Grobbee,Dick de Zeeuw,Carola Grönhagen-Riska,Tanaji Dasgupta,David Lewis,William G. Herrington,Marion Mafham,William Majoni,K Wallendszus,Richard H. Grimm,Terje R. Pedersen,Jonathan A. Tobert,Jane Armitage,Alex Baxter,Christopher Bray,Yiping Chen,Zhengming Chen,Michael Hill,Carol Knott,Sarah Parish,David Simpson,Peter Sleight,Alan Young,Rory Collins +49 more
TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
Journal ArticleDOI
Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
Zhengming Chen,Lixin Jiang,Yiping Chen,J X Xie,Hongchao Pan,Richard Peto,Rory Collins,Lisheng Liu,Commit (ClOpidogrel) +8 more
TL;DR: In a wide range of patients with acute MI, adding clopidogrel 75 mg daily to aspirin and other standard treatments (such as fibrinolytic therapy) safely reduces mortality and major vascular events in hospital, and should be considered routinely.
Journal ArticleDOI
Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray,Richard Haynes,Jemma C. Hopewell,Sarah Parish,Theingi Aung,Joseph Tomson,K Wallendszus,Martin Craig,Lixin Jiang,Rory Collins,Jane Armitage +10 more
TL;DR: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase therisk of serious adverse events.
Journal ArticleDOI
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study
Koon K. Teo,Stephanie Ôunpuu,Steven Hawken,Pandey,Vicent Valentin,David M. Hunt,Rafael Diaz,Wafa Rashed,Rosario V. Freeman,Lixin Jiang,Xiaofei Zhang,Salim Yusuf +11 more
TL;DR: All forms of tobacco use, including different types of smoking and chewing tobacco and inhalation of SHS, should be discouraged to prevent cardiovascular diseases.
Journal ArticleDOI
Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo- controlled trial
Zhengming Chen,Hongchao Pan,Yiping Chen,Richard Peto,Rory Collins,Lixin Jiang,J X Xie,Lisheng Liu,Commit (ClOpidogrel) +8 more
TL;DR: The use of early beta-blocker therapy in acute MI reduces the risks of reinfarction and ventricular fibrillation, but increases the risk of cardiogenic shock, especially during the first day or so after admission.